<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942134</url>
  </required_header>
  <id_info>
    <org_study_id>S-484/2016</org_study_id>
    <nct_id>NCT02942134</nct_id>
  </id_info>
  <brief_title>Acute Dyspnea After Use of Non-invasive Ventilation in COPD and Emphysema (Deventilation Syndrome)</brief_title>
  <official_title>Acquisition and Evaluation of Augemented Dyspnea After Use of Non-invasive Ventilation in Patients With COPD and Empysema (Deventilation Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Felix JF Herth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute dyspnea after use of non-invasive ventilation (NIV) is a common phenomenon in patients&#xD;
      with COPD and emphysema. This trial aims to document incidence and severity of augmented&#xD;
      dyspnea in patients with long term NIV therapy. These findings may help in understanding the&#xD;
      pathomechanisms that lead to post-NIV dyspnea and thus give way to potential therapy schemes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-invasive ventilation (NIV) is a widespread therapy option for patients with hypercapnic&#xD;
      failure due to COPD and emphysema. Augmented dyspnea after use of NIV is commonly found and&#xD;
      leads not only to high patient discomfort, but can also be associated with acute respiratory&#xD;
      failure. This monocentric obervation trial includes patients with COPD III°-IV° (GOLD) and&#xD;
      emphysema and an established long term NIV therapy. During their routine inpatient follow-up,&#xD;
      we will extend the routine examinations, focussing on the vulnerable first hour after the&#xD;
      nocturnal use of NIV. This includes monitoring of breath rate, heart rate, pulsoxymetry,&#xD;
      trancutaneous CO2, blood pressure and capillary blood gas analysis. Sonographic measurement&#xD;
      of diaphragm movement and thickness will be complemented. Subjective dyspnea will be&#xD;
      documented by use of the BORG scale.&#xD;
&#xD;
      By collecting this data, we hope to understand the pathomechanisms causing augmented dyspnea&#xD;
      after NIV and thus provide information for therapeutical concepts to prevent it.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of acute dyspnea after use of non-invasive Ventilation in COPD and emphysema</measure>
    <time_frame>May 2018</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Obstructive Chronic Bronchitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hypercapnic failure due to COPD III to IV GOLD and emphysema on long&#xD;
        term noninvasive ventilation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females with stabile COPD, last exacerbation over one month,&#xD;
&#xD;
          -  GOLD III to IV&#xD;
&#xD;
          -  Regular use of noninvasive ventilation, more than four hours per day for more than one&#xD;
             year&#xD;
&#xD;
          -  Signed declaration of consent&#xD;
&#xD;
          -  Sufficient language capabilities, german&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute exacerbation in the past four weeks&#xD;
&#xD;
          -  Acute pulmonary embolus&#xD;
&#xD;
          -  Haemoptysis&#xD;
&#xD;
          -  Severe neurological disease&#xD;
&#xD;
          -  Severe cardiological disease&#xD;
&#xD;
          -  Haemodynamic instability&#xD;
&#xD;
          -  New hypoxia or worsening of hypercapnia more than twenty percent of usual rate&#xD;
&#xD;
          -  Acute pneumothorax&#xD;
&#xD;
          -  Other instable Situation, for example intraabdominal bleedings&#xD;
&#xD;
          -  Drug or alcohol dependency&#xD;
&#xD;
          -  Regular intake of morphium&#xD;
&#xD;
          -  Adiposity BMI over 35&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix FJ Herth, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Director Thoraxklinik Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mavi D Schellenberg, Dr.med.</last_name>
    <phone>00496221-3968027</phone>
    <email>mavi.schellenberg@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix FJ Herth, Prof.</last_name>
    <phone>00496221-3961201</phone>
    <email>felix.herth@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Felix JF Herth</investigator_full_name>
    <investigator_title>Prof. Dr. med. Felix JF Herth</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

